Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING

Ablation of Renal Masses Outcomes Registry (ARMOR): Ablation Procedure and Quality of Life Assessment

NCT01888198 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to better understand how effective ablation is for destroying tumor cells in the kidney and whether quality of life is improved for patients. Participation in ARMOR may involve retrospective data collection only, combined retrospective and prospective data collection, or prospective data collection

Conditions Studied

Interventions

  • BEHAVIORAL (EORTC QLQ-C30) questionnaire
  • BEHAVIORAL EuroQol EQ-5D 7-item questionnaire

Study Locations (6)

California

  • University of California, Los Angeles — Los Angeles

Maryland

  • University of Maryland Medical Center — Baltimore

New York

  • Memorial Sloan Kettering Cancer Center — New York

Pennsylvania

  • Thomas Jefferson University Hospital — Philadelphia

Rhode Island

  • Rhode Island Hospital — Providence

Texas

  • Md Anderson Cancer Center — Houston

Trial Details

FieldValue
Enrollment Target 294 participants
Start Date 2013-06
Est. Completion 2026-06

Sponsor

Memorial Sloan Kettering Cancer Center

2,280 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01888198

The ClinicalTrials.gov registry entry for NCT01888198 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 294 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 2,280 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Renal Cancer appearing as the primary indexed condition, and to 2 interventions — of which (EORTC QLQ-C30) questionnaire is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT01888198 reports 6 study locations spanning 6 distinct geographic areas — top geographies include California, Maryland, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT01888198 about?

NCT01888198 is a clinical study titled "Ablation of Renal Masses Outcomes Registry (ARMOR): Ablation Procedure and Quality of Life Assessment". The purpose of this study is to better understand how effective ablation is for destroying tumor cells in the kidney and whether quality of life is improved for patients. Participation in ARMOR may involve retrospective data collection only, combined retrospective and prospective data collection, or...

What is the current status of trial NCT01888198?

This trial is currently active not recruiting. The enrollment target is 294 participants. The study started on 2013-06. Estimated completion is 2026-06.

What conditions does trial NCT01888198 study?

This clinical trial studies the following conditions: Renal Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT01888198?

The interventions under investigation include: (EORTC QLQ-C30) questionnaire (BEHAVIORAL), EuroQol EQ-5D 7-item questionnaire (BEHAVIORAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT01888198?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 2,280 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT01888198 being conducted?

This trial has 6 study locations across California, Maryland, New York, Pennsylvania, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial